Rituximab Biosimilar, CD20 Monoclonal Antibody

Additional Information:
| Rituximab Biosimilar, CD20 Monoclonal Antibody Recombinant Humanized IgG1 Monoclonal Antibody. Isotype: Human IgG1 kap|The monoclonal antibody rituximab biosimilar was produced in the Rituximab biosimilar CHO stable cell line. Specificity/Sensitivity: The monoclonal antibody rituximab biosimilar specifically binds to the human TNF alpha. Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological |0.2 uM filtered solution, pH 6.5, no stabilizers or preservatives. Endotoxin: Purity: >95% by SDS-|The monoclonal antibody rituximab biosimilar is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |Background B-lymphocyte antigen CD20 encoded by the MS4A1 gene is an activated-glycosylated phosphoprotein on the surface of all B-cells. The function of the membrane protein is to stimulate B-cell immune response, specifically against T-independent antigens though its natural ligand remains unknown. CD20 is important for the development and different of B-cells into plasma cells. CD20 belongs to the membrane-s|Bevacizumab Biosimilar, research grade (VEGF-A) Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli) Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR) Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR) Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu) Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu) Infliximab biosimilar, research grade (TNF alpha) Adalimumab biosimilar, research grade (TNF alpha) Rituximab biosimilar, research grade (CD20) Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF) Palivizumab Biosimilar, research grade (RSV) Omalizumab biosimilar, research grade (IgE) Eculizumab biosimilar, research grade (C5)